SCHOTT to triple ready-to-use vial production capacity in the US
SCHOTT is to triple its glass vial production capacity at its site in Lebanon, PA.
In doing so, the company will further strengthen its business for ready-to-use (RTU) solutions, which have emerged as an often preferred drug containment alternative for high-value medications.
“With our investment, we are underlining our commitment to the global pharma industry and particularly the US market. Additionally, we are enhancing our regional manufacturing footprint in Lebanon, Pennsylvania, where we are proudly celebrating our site’s 30th anniversary,” said Andreas Reisse, Executive Vice President of SCHOTT Pharma.
The RTU vials known under the brand name adaptiQ are particularly suitable for drugs, such as biologics and vaccines, including upcoming technologies like mRNA-based drugs.
The solution enables pharma companies to efficiently perform pre-clinical and clinical trials as well as commercial filling. “We are increasing our production capacity intending to meet the growing need for this product category and contribute to bringing the latest life-saving treatments to patients faster,” said Hakan Gerdan, who was appointed as SCHOTT’s new Plant Manager in Lebanon, PA at the start of 2022.
The adaptiQ® vials are made from FIOLAX Type I borosilicate glass.
During the filling process, the vials remain fixed in a standardized tub, which is the same tub also utilized for other drug containment and delivery solutions such as prefillable syringes and cartridges.
The use of a standard tub simplifies the filling process for pharma companies as it offers greater flexibility when switching between different drug containment solutions, thereby reducing costs and time-to-market.
Image: Robert Lindner, Global Product Manager SCHOTT adaptiQ, holding an adaptiQ vial, nest, and tub.
